Strategic in-licensing and collaboration agreement

CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In -Licensingand Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases
 
CRISPR Therapeutics Gains Exclusive Worldwide License to Proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) Technology with Initial Research Focused on Duchenne Muscular Dystrophy